The FDA on May 5 approved AstraZeneca and Daiichi Sankyo’s Enhertu for earlier use in metastatic, HER2+ breast cancer patients. The antibody treatment is currently approved as a third-line therapy, and can now be used as a second-line therapy in patients with recurring disease within six months of receiving a different HER2 inhibitor. As a breast cancer therapy, Enhertu currently holds covered or better status for 63% of all insured lives under the pharmacy benefit. Under the medical benefit, the drug holds 78% covered or better status.
SOURCE: MMIT Analytics, as of 5/11/22